about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsBoceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsLiver stiffness using transient elastography is applicable to canines for hepatic disease models.Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patientsUse of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study.[GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)].Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansPersistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune responseProgression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis CLiver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation.Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).Executive summary of the consensus document on the management of renal disease in HIV-infected patients.Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.Impact of age and cytomegalovirus on CD8+ T-cell compartment remodeling after solid organ transplantation: A one-year follow-up study.Current views on interferon therapy for HIV.Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study.Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Hepatitis E Virus (HEV) Infection in Anti-HEV Immunoglobulin G-Carrying Patients After Successful Hepatitis C Virus Treatment: Reactivation or Reinfection?Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption.Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.
P50
Q26740117-16D10C04-61F4-4502-9341-C141A0924F27Q33422417-6A7AE087-8619-44F7-92AF-7E2F786AB28AQ33423922-A5B34724-2BD8-4A23-AA30-9A8EEB2AAD10Q33430704-40E012BD-57AC-4D18-9373-5078328B69F6Q33638134-77194B9A-5051-4DCF-B492-3A655BC9DF86Q33761542-A2121B74-0949-44F8-8B25-A182E188F0C9Q33778756-1C7E2E3E-D67B-437E-BB4C-0D1BD3664453Q33889885-26E065A3-5398-4B7D-95CE-B988862C42E6Q34388010-6C546735-7EA6-4DD5-969D-4D8AE88209EBQ34473823-3D07BD08-B1A1-4884-A39D-E0199ED78B07Q34477067-0F94FE49-85C7-462C-8103-D7930D8E17AAQ34558710-460B7E95-BAD3-44BA-8EA4-2CF0B9632ADEQ34852032-4EA7C889-E4AE-4675-AF57-85EB6911517DQ35153222-B3BBDE99-840B-41FF-87D3-6882DAF57216Q35219896-6C71AA70-8B77-48DB-BD96-6A3585E7DFCEQ35862847-B6C8D4AF-2432-4785-BBB6-81D0B5E6B3FFQ35915593-1081E972-317F-406F-8473-D501FF6E13E6Q36167452-17C6175A-E5A0-40C5-924E-35D7618F6C14Q36553967-0A431695-DEFE-4F7F-B2AE-417F50E522E9Q36718901-3A576D58-1DA9-4844-AA48-C75330BA00F0Q37374672-D8602CFC-A67F-48CC-ACE0-1253DFC9938BQ37642114-66823CEF-5889-4DFF-96A9-CBB0361C6605Q38081351-4525F410-B160-4FDF-95CB-03E9FD6F77AAQ38225483-2AA87CA0-2D6E-4A02-A715-AF4F49FAABFBQ38270322-2E85BE5C-D9D7-4D82-AA3C-6BE065222023Q38500364-0A5BCCD9-C8BB-4B6D-8D12-EA0592A71558Q38688390-45697BBB-5EC1-423F-BA2E-125A5D761B19Q38860634-778615DE-B0F4-4E2C-AC9D-214A350E1E1CQ38942836-7E5A1893-EF5D-4318-A4F6-31712589331AQ38976791-D9E9755C-AD8F-430A-B44E-E0568DDC6697Q38995024-8ECB0F30-DC9E-4089-A353-B5FD67B14ACAQ39717761-CBF61C77-A31C-4971-90AE-A970C62C9C16Q39877513-66FEA2E8-799F-40CF-88BF-D2C967292CC2Q40137776-2414EA8F-3565-423B-8002-F97FF486F7A0Q40190578-6C9FA627-0812-4D31-8EA0-C76FFCF992C9Q40328514-353ACE75-59AE-4C06-B0CB-57B21E5C30F2Q40360505-49D0D811-978F-4989-8EA5-767B1276F04CQ40376036-62F03425-56BB-43B1-B46F-27A58D29BFA3Q40379673-E288D0AA-69C6-4D08-9B68-6751538EE59CQ40439142-127C8D45-F4DB-409C-BC37-15EF94180344
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
A Rivero
@ast
A Rivero
@en
A Rivero
@es
A Rivero
@nl
type
label
A Rivero
@ast
A Rivero
@en
A Rivero
@es
A Rivero
@nl
prefLabel
A Rivero
@ast
A Rivero
@en
A Rivero
@es
A Rivero
@nl
P106
P31
P496
0000-0001-5005-8268